Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents (ADAPT-DES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00638794|
Recruitment Status : Completed
First Posted : March 19, 2008
Last Update Posted : January 23, 2013
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Coronary Artery Disease||Device: Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|
- the frequency, timing and correlates (clinical and angiographic) of drug-eluting stent (DES) thrombosis in a patient population with few clinical and angiographic exclusion criteria,
- the relationship of aspirin and/or clopidogrel hyporesponsiveness, and general platelet reactivity to early and late DES thrombosis in separate phases stratified by whether the patient is taking dual (aspirin plus clopidogrel) or single (aspirin alone) antiplatelet therapy, and
- combining the findings from the above 2 objectives, to identify a cohort representing a significant proportion of all patients at increased risk to have early and/or late DES stent thrombosis.
|Study Type :||Observational|
|Actual Enrollment :||8575 participants|
|Official Title:||Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||January 2013|
Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
Device: Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)
PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
Other Name: Taxus™, Cypher®, Endeavor™, Xience V™
- Definite or probable stent thrombosis using the Academic Research Consortium (ARC) definition, primary events only. [ Time Frame: 30 days, 1 year, 2 year ]
- ARC definite, probable, possible or any stent thrombosis, utilizing primary only and then primary + secondary thromboses; death, MI, recurrent ischemia necessitating repeat target lesion and target vessel intervention and MACE. [ Time Frame: 1 day, 30 days, 1 year, 2 year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Patients undergoing PCI in whom at least one DES is implanted and in whom PCI of all treated lesions is successful (diameter stenosis <30% with TIMI 3 flow in all treated lesions) without major complications (defined as freedom from procedural death, intra-procedural stent thrombosis, procedural myocardial infarction or sustained vessel closure, or need for emergency bypass graft surgery). One or more bare metal stents (BMS) may be implanted, and other lesions may be treated without stenting as long as at least one DES is implanted. However, the procedure must be successful and uncomplicated (as defined above) for all lesions (DES + BMS + non-stent).
- Aspirin use: Adequate aspirin loading given prior to PCI: at least 300 mg non enteric coated oral aspirin at least 1 hour prior to the procedure or 324 mg chewed or 250 mg IV aspirin at least 30 minutes prior to the procedure.
- Patient has Hematocrit between 30 and 52% and Platelet Count greater than 100,000/µl.
- For US sites: Only FDA-approved DES stents may be used in this study. For OUS sites: Only DES stents that are CE marked for approval may be used in this study.
- PCI performed with unfractionated or low molecular weight heparin, or bivalirudin as the procedural antithrombin.
- Patient or guardian able to provide informed written consent.
Patients in whom blood for Accumetrics VerifyNow platelet function testing cannot be drawn after the minimum clopidogrel loading duration and Glycoprotein (GP) IIb/IIIa inhibitor washout duration as follows:
- Clopidogrel loading: Clopidogrel loading pre PCI is recommended, but post PCI clopidogrel loading is acceptable per standard of care. In all patients (whether or not clopidogrel is initiated pre or post PCI), prior to blood drawing for VerifyNow platelet function testing, a 600 mg loading dose must have been given at least 6 hours prior, or a 300 mg loading dose must have been given at least 12 hours prior, or the patient must have been maintained on at least 75 mg of clopidogrel daily for at least 5 days.
- GP IIb/IIIa inhibitor washout: Eptifibatide or tirofiban must have been discontinued for at least 24 hours prior to VerifyNow platelet function testing. Abciximab must have been discontinued for at 10 days prior to VerifyNow platelet function testing.
- Inability of the VerifyNow system to measure either Aspirin, P2Y12 or IIb/IIIa platelet responsiveness.
- Severe allergy to stainless steel, contrast dye, all anti-thrombin agents (unfractionated and low molecular weight heparin and bivalirudin), aspirin or clopidogrel that cannot be adequately pre-medicated.
- Concurrent enrollment in another trial that involves an investigational stent, antithrombotic or antiplatelet agent. Patient in other investigational trials that have not reached their primary endpoint may be enrolled in ADAPT-DES as long as the other trials do not involve an investigational stent, antithrombotic or antiplatelet agent and inclusion of such patient will have no effect on the endpoint of either study.
- Patients in whom bypass graft surgery is planned within 2 years.
- Patients with stent thrombosis before the performance of pre-discharge VerifyNow platelet function testing.
- Patients unwilling or unable to complete clinical follow-up for the duration of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00638794
|United States, Minnesota|
|Minneapolis Heart Institute|
|Minneapolis, Minnesota, United States, 55407|
|United States, New York|
|Columbia University Medical Center & New York Presbyterian|
|New York, New York, United States, 10027|
|United States, North Carolina|
|Carolinas Medical Center|
|Charlotte, North Carolina, United States, 28202|
|LeBauer Cardiovascular Research|
|Greensboro, North Carolina, United States, 27401|
|FirstHealth Moore Regional Hospital|
|Pinehurst, North Carolina, United States, 28374|
|United States, Ohio|
|Ohio State University Medical Center|
|Columbus, Ohio, United States, 43210|
|United States, Pennsylvania|
|Lehigh Valley Hospital and Health Network|
|Allentown, Pennsylvania, United States, 18105|
|United States, Tennessee|
|Wellmont Holston Valley Medical Center|
|Kingsport, Tennessee, United States, 37660|
|Principal Investigator:||Gregg W. Stone, MD||CardioVascular Research Foundation|
|Responsible Party:||Cardiovascular Research Foundation, New York|
|Other Study ID Numbers:||
|First Posted:||March 19, 2008 Key Record Dates|
|Last Update Posted:||January 23, 2013|
|Last Verified:||August 2012|
Coronary Artery Disease
Arterial Occlusive Diseases